In the phase III MIRAI randomized trial of 386 participants with major depressive disorder (MDD) and an inadequate response to their current antidepressant therapy, 6 weeks of treatment with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback